|
|
|
|
| Chairpersons: |
G.M. Kostner, Austria
U. Beisiegel, Germany
|
| 08:30 |
A CENTURY OF CHOLESTEROL AND CORONARIES
J. Goldstein, USA |
| Chairpersons: |
M. Rudling, Sweden
H. Greten, Germany
|
| 09:30 |
THE UNSTABLE ATHEROSCLEROTIC PLAQUE: DETECTION AND
TREATMENT
J. Muller, USA
|
| 10:00 |
IMMUNOLOGY
OF ATHEROSCLEROSIS
G. Wick, Austria
|
| 10:30 |
Coffee Break, Poster Viewing and Exhibition Visit |
EVOLVING TACTICS IN THE BATTLE
AGAINST ATHEROSCLEROSIS
Educational Symposium sponsored by Merck Sharp &
Dohme |
| Chairpersons: |
S. Grundy, USA
J. Betteridge, UK
|
| 11:00 |
INTRODUCTION
S. Grundy, USA |
| 11:05 |
WHAT LIPIDOLOGISTS SHOULD KNOW ABOUT STEROL REGULATORY
ELEMENT BINDNG PROTEINS
J. Goldstein, USA |
| 11:25 |
CURRENT THERAPEUTIC APPROACHES IN TREATING PATIENTS
WITH DIABETES
S. Grundy, USA |
| 11:45 |
MRC/BHF HEART PROTECTION STUDY: WIDENING THE INDICATION
FOR HIGH RISK PATIENTS
R. Collins, UK |
| 12:05 |
HOW WILL THE HEART PROTECTION STUDY CHANGE OUR TREATMENT
OF PEOPLE WITH DIABETES
J. Betteridge, UK |
| 12:25 |
PANEL DISCUSSION
All Speakers |
| 12:55 |
CLOSING REMARKS
J. Betteridge, UK |
| 13:00 |
Lunch Break, Poster Viewing and Exhibition Visit |
A NEW BEGINNING FOR STATIN THERAPY
Educational Symposium sponsored by AstraZeneca |
| Chairpersons: |
J. Chapman, France
J. Shepherd, UK |
| |
INTRODUCTION
J. Chapman, France |
| |
MANAGING THE HIGH-RISK PATIENT - THERAPEUTIC APPROACHES
IN 2002
H. Schuster, Germany |
| |
DISCUSSION |
| |
SURROGATE MARKERS OF ATHEROSCLEROSIS: IMPACT
OF STATINS
J. Kastelein, The Netherlands |
| |
DISCUSSION |
| |
STATIN INHIBITION OF HMG-COA REDUCTASE: A 3-DIMENSIONAL
VIEW
E. Istvan, USA |
| |
STATINS: DIFFERENCES AND BENEFITS
F. McTaggart, UK |
| |
DISCUSSION |
| |
HDL-C IN ATHEROSCLEROSIS, ACTOR OR BYSTANDER
E. Schaefer, USA |
| |
DISCUSSION |
Workshop 19: Session 1
STATINS: OLD DRUGS AND NEW DEVELOPMENTS |
| Chairpersons: |
K.M. Kostner, Austria
J. Davignon, Canada
|
| 15:00 |
STATINS:
OLD DRUGS AND NEW DEVELOPMENTS - THE ROLE OF STATINS IN
DIABETIC DYSLIPIDAEMIA
D.J. Betteridge, UK
|
| 15:25 |
POSSIBLE
ROLE OF STATINS AS AN ADJUVANT THERAPY IN CANCER
P. Fraunberger, B. Siegele,
A. Heim, D. Seidel, A.K. Walli, Germany
|
| 15:38 |
ROSUVASTATIN
REDUCES ATHEROSCLEROSIS INDEPENDENTLY OF ITS CHOLESTEROL-LOWERING
EFFECT IN APOE3*LEIDEN TRANSGENIC MICE
L.M.Havekes, W. Van Duyvenvoorde,
M.C.E. Maas, H. Van Der Boom,
C.M. Van Den Hoogen, J.J. Emeis, H.M.G. Princen,
The Netherlands
|
| 15:51 |
STATIN
TREATMENT ASSESSED BY MAGNETIC RESONANCE
J.P. Albertini, H. Laouenan,
P. Valensi, L. Le Moyec, France
|
| 16:04 |
EFFECT
OF ATORVASTATIN ON THE KINETICS OF APOLIPOPROTEIN AIV
IN NON INSULIN DEPENDENT DIABETICS
F. Ferrer, H. Nazih, K. Ouguerram,
M. Krempf, H. Laouenan,
J-M. Bard, France
|
| 16:17 |
MEDITERRANEAN DIET AND LOW FAT DIETS ARE ASSOCIATED
WITH SIMILAR LIPID LEVELS AT 1 YEAR IN PATIENTS WITH CORONARY
HEART DISEASE ON STATIN THERAPY
D. Colquhoun, P. Glasziou, S. Somerset, S. Pirozzo,
P. Horsley, K.M. Irish,
J. Weyers, Australia |
| 16:30 |
Coffee Break, Poster Viewing and Exhibition Visit |
Workshop 2: Session 1
CHOLESTEROL HOMEOSTASIS OF THE CELL |
| Chairpersons: |
L. Rudel, USA
J. Smith, Australia |
| 15:00
|
ACAT
2 REGULATION IS IMPORTANT TO DIET-INDUCED HYPERCHOLESTEROLEMIA
IN PRIMATES
L.L. Rudel, M.A. Davis, J.K.
Sawyer, R. Shah, J.M. Wallace, USA
|
| 15:25 |
QUANTITATIVE
EXPRESSION OF ACAT-1 AND ACAT-2 GENES IN HUMAN LIVER AND
DUODENUM BY REAL-TIME PCR
K. Rangaray, R. Simpson, D.J. MacLean,
L.K. Nathanson, K.A. Stuart,
S.P. Scott, J. De Jersey, J. Smith, Australia
|
| 15:50 |
PLEIOTROPIC
ANTIATHEROSCLEROTIC EFFECT OF LIPOPHILIC CALCIUM ANTAGONISTS
IN MACROPHAGES
F. Bernini, N. Baldini, I.
Zanotti, M. Canavesi, E. Favari, S. Bellosta, Italy
|
| 16:03 |
INHERITANCE
OF CHOLESTEROL SYNTHESIS AND ABSORPTION IN FAMILIES WITH
CORONARY HEART DISEASE
H. Gylling, T.A. Miettinen,
Finland
|
| 16:16 |
ANALYSIS
OF THE PEROXISOME-DEFICIENT PEX2 ZELLWEGER MOUSE: ALTERATION
IN CHOLESTEROL HOMEOSTASIS
W.J. Kovacs, K. Tape, J.E.
Shackelford, S.J. Fliesler, P.L. Faust,
S.K. Krisans, USA
|
| 16:30 |
Coffee Break, Poster Viewing and Exhibition Visit
|
Workshop 13: Session 1
MANAGEMENT OF THE HYPER- AND DYSLIPOPROTEINEMIC PATIENT:
FOCUS ON DM, KIDNEY DISEASES AND ON CHILDREN |
| Chairpersons: |
O. Pachinger, Austria
L. Ose, Norway
|
| 15:00 |
TREATMENT
OF FAMILIAL HYPERCHOLESTEROLEMIA(FH) IN CHILDREN
L. Ose, Norway
|
| 15:25
|
INSULIN
RESISTANCE AND CHD IN FAMILIAL COMBINED HYPERLIPIDEMIA
(FCH)
R. Carmena, J.F. Ascaso,
J.T. Real, Spain
|
| 15:50 |
IMPORTANCE
OF LIPIDS FOR THE DEVELOPMENT OF EARLY NEPHROPATHY IN
TYPE 2 DIABETES
S. Ljubic, B. Brkljacic,
N. Crkvencic, R. Mesic, Croatia
|
| 16:03 |
LOW
HDL-CHOLESTEROL BUT NOT HIGH TRIGLYCERIDES LEVELS ARE
RELATED TO INTIMA-MEDIA THICKENING IN RECENTLY DIAGNOSED
TYPE 2 DIABETES
E. Brocco, G.L. Guarnieri,
A. Breda, M. Scarpel, C. Bravin, A. Gasparoni,
F. Giacon, E. Feltrin, A. Maccioni, Italy
|
| 16:16 |
GRANULOCYTE
INTEGRIN PATTERN IN DIABETES MELLITUS WITH MACROVASCULAR
COMPLICATIONS
G. Caimi, C. Carollo, M. Montana, B. Canino, A.
Catania, R. Lo Presti, Italy |
| 16:30 |
Coffee Break, Poster Viewing and Exhibition Visit
|
Workshop 9: Session 1
INFLAMMATION,PHOSPHOLIPASES AND IMMUNOLOGICAL
ASPECTS OF ATHEROSCLEROSIS |
| Chairpersons: |
O. Wiklund, Sweden
Z. Reiner, Croatia
|
| 15:00 |
INFECTION
AND ATHEROSCLEROSIS - THE POSSIBLE ROLE OF ANTIBIOTICS
IN CORONARY HEART DISEASE (CHD) TREATMENT
Z. Reiner, Croatia
|
| 15:25 |
SUPPRESSION
OF INFLAMMATION MARKERS AND CELLULAR IMMUNE FUNCTION IN
OBESE (OB/OB) MICE
Z. Berke, M. Kjerrulf, N.
Oakes, E. Hurt-Camejo, Sweden
|
| 15:38 |
AUGMENTED
MONOCYTIC PROINFLAMMATORY CYTOKINES IN ACUTE CORONARY
SYNDROMES: RELATION WITH PLAQUE INFLAMMATION AND RUPTURE,
AND WITH NEOINTIMAL THICKENING
J.M. Bosmans, A.J. Schuerwegh,
L.S. De Clerck, F.L. Wuyts,
M.M. Kockx, W.J. Stevens, C.J. Vrints, Belgium
|
| 15:51 |
SUPERFICIAL
FEMORAL ARTERY OCCLUSION AND MARKER OF INFLAMMATION
G. Strubel, K. Kroeger, G.
Rudofsky, Germany
|
| 16:04 |
T
LYMPHOCYTE FUNCTIONS MEDIATED BY OXLDL IN RELATION TO
ATHEROSCLEROSIS
T. Fulop, N. Douxiech, A.
Larbi, A. Khalil, Canada
|
| 16:17 |
FACTOR
V LEIDEN AND RISK OF ARTERIAL THROMBOSIS: 3 CASE-CONTROL
AND 3 PROSPECTIVE STUDIES BASED ON THE COPENHAGEN CITY
HEART STUDY AND 2 META-ANALYSES
K. Juul, A. Tybjaerg-Hansen, R.
Steffensen, S. Kofoed, G. Jensen,
B.G. Nordestgaard, Denmark
|
| 16:30 |
Coffee Break, Poster Viewing and Exhibition Visit
|
Workshop 20:
SYNDROME -X, FCHL, sd-LDL |
| Chairpersons: |
M. Hanefeld, Germany
S. Muntoni, Italy |
| 15:00 |
NEW
DEVELOPMENTS IN FAMILIAL COMBINED HYPERLIPIDEMIA (FCH)
A.F.H. Stalenhoef, M.J. Veerkamp,
J. DeGraaf, The Netherlands
|
| 15:25 |
INSULIN RESISTANCE AND THE METABOLIC SYNDROME IN THE
SAPHIR POPULATION
B. Paulweber , Austria
|
| 15:50 |
IN
VIVO METABOLISM OF LDL-SUBFRACTIONS
H.C. Geiss, S. Bremer, P.H.R.
Barrett, C. Otto, K.G. Parhofer , Australia
|
| 16:03 |
LOW
CARDIORESPIRATORY FITNESS IS ASSOCIATED WITH THE METABOLIC
SYNDROME IN MIDDLE-AGED MALE EXECUTIVES
I.J. Kullo, D.D. Hensrud,
T.G. Allison, USA
|
| 16:16 |
LDL
PARTICLE SIZE IS RELATED TO CIRCULATING OXIDISED LDL,
BUT NOT TO IN VITRO OXIDISABILITY
P.G. Scheffer, G. Bos, J.M.
Dekker, R.J. Heine, T. Teerlink, The Netherlands
|
| 16:30 |
Coffee Break, Poster Viewing and Exhibition Visit
|
| Chairpersons: |
W. Schneider, Austria
T. Kita, Japan
|
| 15:00 |
OXIDIZED
LDL RECEPTORS AND ATHEROSCLEROSIS
T. Kita, Japan
|
| 15:25 |
ADAPTERS
FOR LIPOPROTEIN RECEPTORS AT THE CROSSROAD OF ENDOCYTOSIS
AND SIGNALING
J. Nimpf, Austria
|
| 15:50 |
HOW
A RECEPTOR FOR OXIDIZED LOW DENSITY LIPOPROTEINS WORKS
IN HUMANS. INSIGHTS FROM HUMAN CD36 DEFICIENCY
K-I. Hirano, T. Kuwasako,
Y. Nakagawa-Toyama, T. Sugimoto, M. Ishigami,
N. Sakai, S. Yamashita, Y. Matsuzawa, Japan
|
| 16:03 |
CONSTRUCTION
OF HIGH-CAPACITY VIRAL VECTORS FOR OVEREXPRESSION OF FULL-LENGTH
LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN (LRP)
A. Laatsch, J. Heeren, U.
Beisiegel, F. Schnieders, Germany
|
| 16:16 |
A
COMMON MUTATION IN THE LOW DENSITY LIPOPROTEIN RECEPTOR
IS ASSOCIATED WITH A THREE-FOLD RISK OF STROKE. THE COPENHAGEN
CITY HEART STUDY
A. Tybjaerg-Hansen, R. Frikke-Schmidt,
B.G. Nordestgaard, P. Schnohr,
Denmark
|
| 16:30 |
Coffee Break, Poster Viewing and Exhibition Visit |
Workshop 4:
ETHNOMEDICAL ASPECTS OF OBESITY |
| Chairpersons: |
B. Kostner, Austria
A. Prinz, Austria
|
| 15:00 |
LARGE
BODY SIZE - A POLYNESIAN PERSPECTIVE
N.J. Pollock, New Zealand
|
| 15:25 |
TREATMENT
OF OBESITY WITH TRADITIONAL CHINESE MEDICINE
B. Kostner, Austria
|
| 15:50 |
OBESITY
AND FATNESS AMONG THE AZANDE, CENTRAL AFRICA
A. Prinz, Austria
|
| 16:15 |
FIVE
YEAR PREVALENCE IN CORONARY RISK FACTORS IN RURAL MALAYSIA
K. Yusoff, S. Singh, M.D.
Sulaiman, A. Pit, H. Yunus, H. Nawawi, Malaysia
|
| 16:30 |
Coffee Break, Poster Viewing and Exhibition Visit |
Workshop 19: Session 2
STATINS: OLD DRUGS AND NEW DEVELOPMENTS |
| Chairpersons: |
W. Riesen, Switzerland
W. Klein, Austria
|
| 17:00 |
SHORT TERM EFFECTS OF ATORVASTATIN
ON COAGULATION AND INFLAMMATION
W.F. Riesen, W. Korte, H.
Engler, G. Noseda, Switzerland
|
| 17:25 |
DOSE-DEPENDENT
ACTION OF ATORVASTATIN ON CETP ACTIVITY, ATHEROGENIC APOB-CONTAINING
LIPOPROTEINS AND CELLULAR FREE CHOLESTEROL EFFLUX IN TYPE
IIB HYPERLIPIDEMIA
M. Guerin, P. Egger, W. Le
Goff, C. Soudant, A. Van Tol, R. Dupuis,
M.J. Chapman, The Netherlands, France
|
| 17:38 |
PLASMA
APOE PRODUCTION IS REDUCED BY ATORVASTATIN TREATMENT IN
PATIENTS WITH COMBINED HYPERLIPIDEMIA
J.S. Cohn, M. Tremblay, R.
Batal, H. Jacques, L. Veilleux, C. Rodriguez,
P.H.R. Barrett, D. Dubreuil, M. Roy, L. Bernier, O.
Mamer, J. Davignon,
Canada, USA
|
| 17:51 |
SIMVASTATIN
STABILIZES ATHEROSCLEROTIC PLAQUES BY INHIBITING CYCLOOXYGENASE-2
DEPENDENT METALLOPROTEINASE ACTIVITY
F. Cipollone, M. Fazia, A.
Iezzi, M. Zucchelli, D. De Cesare, B. Pini,
S. Ucchino, F. Spigonardo, G. Bajocchi, F. Chiarelli,
M. Bucci,
F. Cuccurullo, A. Mezzetti , Italy
|
| 18:04 |
LONG-TERM
TREATMENT EFFECT OF ATORVASTATIN ON AORTIC ELASTICITY
IN HYPERCHOLESTEROLEMIC PATIENTS
V.G. Athyros, A.G. Kontopoulos,
A.N. Pehlivanidis, D.S. Dimitriadis,
A.A. Papageorgiou, H. Boudoulas, Greece, USA
|
| 18:18 |
EFFECT OF ATORVASTATIN AND OTHER HMG-COA
REDUCTASE INHIBITORS ON THE METABOLISM OF TRIAGLYCERIDES
IN CULTURED CELLS
H. Scharnagl, H. Gierens, M. Nauck, H. Wieland,
W. März, Germany, Switzerland |
Workshop 2: Session 2
CHOLESTEROL HOMEOSTASIS OF THE CELL |
| Chairpersons: |
S. Levak-Frank, Austria
C.D. Moutafis, Greece
|
| 17:00 |
REGULATION
OF HEPATIC CHOLESTEROL METABOLISM
M. Rudling, C. Gälman,
B. Angelin, Sweden
|
| 17:25 |
BODY
CHOLESTEROL HOMEOSTASIS AND POOLS: THEIR CLINICAL SIGNIFICANCE
C.D. Moutafis, Greece
|
| 17:50 |
DISORDER
OF CELL CHOLESTEROL TRAFFIC IN NIEMANN-PICK TYPE C DISEASE:
ANALYSIS OF MUTATIONS OF NPC-1 GENE
P. Tarugi, G. Ballarini,
F. Panzani, S. Calandra, Italy
|
| 18:03 |
INCREASED
EXPRESSION OF ARGINASE I IN MACROPHAGES FROM ATHEROSCLEROSIS
RESISTANT RABBITS
D. Teupser, R. Burkhardt, W. Wilfert,
J. Wilde, C. Tennert, D. Kretzschmar,
F. Jeromin, M. Leonhardt, J. Thiery, Germany
|
| 18:16 |
TRANSCRIPTIONAL
REGULATION OF MACROPHAGE LIPOPROTEIN LIPASE GENE EXPRESSION:
IDENTIFICATION OF NOVEL PATHWAYS FOR CYTOKINE ACTION
D.P. Ramji, T.R. Hughes,
J.R. Mead, S.A. Irvine, S. Evans, UK
|
Workshop 13: Session 2
MANAGEMENT OF THE HYPER- AND DYSLIPOPROTEINEMIC PATIENT:
FOCUS ON DM, CEREBROVASCULAR ATHEROSCLEROSIS,
KIDNEY DISEASES AND ON CHILDREN |
| Chairpersons: |
P. Schwandt, Germany
M. Mancini, Italy
|
| 17:00 |
OPTIMAL
TREATMENT OF DYSLIPIDEMIA IN PATIENTS WITH TYPE 2 DIABETES
M-R. Taskinen, Finland
|
| 17:25 |
UNDERTREATMENT
OF DYSLIPOPROTEINEMIA IN CARDIOVASCULAR DISEASES
P. Schwandt, G-M. Haas, Germany
|
| 17:50 |
EFFECT
OF COLESEVELAM HCL, A NOVEL BILE ACID SEQUESTRANT, ON
LDL PARTICLE SIZE IN PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA
J. Isaacsohn, P. Jones ,
USA
|
| 18:03 |
DIFFERENT
RISK FACTORS FOR PERIPHERAL VASCULAR CALCIFICATION BETWEEN
DIABETIC AND NON-DIABETIC HEMODIALYSIS PATIENTS - IMPORTANCE
OF GLYCEMIC CONTROL
E. Ishimura, S. Okuno, S.
Kitatani, M. Kim, T. Shoji, M. Inaba,
Y. Nishizawa, Japan
|
| 18:16 |
PPARGC1/PGC1
GENE LOCUS: ASSOCIATIONS WITH OBESITY INDICES AND DIABETES
RISK
H. Esterbauer, H. Oberkofler,
V. Linnemayr, B. Iglseder, M. Hedegger,
P. Wolfsgruber, B. Paulweber, G. Fastner, F. Krempler,
W. Patsch, Austria
|
Workshop 9: Session 2
INFLAMMATION, PHOSPHOLIPASES AND
IMMUNOLOGICAL ASPECTS OF ATHEROSCLEROSIS |
| Chairpersons: |
E. Hurt-Camejo, Sweden
E. Leitersdorf, Israel
|
| 17:00 |
POTENTIAL
CONTRIBUTION OF PHOSPHOLIPASE A2 ACTIVITY IN ATHEROSCLEROSIS
E. Hurt-Camejo, B. Rosengren,
H. Peilot, C. Hallberg, G. Camejo, Sweden
|
| 17:25 |
STUDIES
ON ANTIBODIES TO HUMAN AND BACTERIAL 60 KD HEAT SHOCK
PROTEINS: JOINT ASSOCIATION WITH CORONARY ARTERY DISEASE
Z. Prohaszka, I. Karadi,
N. Hosszufalusi, L. Romics, M. Singh, G. Fust, Hungary,
Germany
|
| 17:38 |
LEVELS
OF OXIDATIVE STRESS ARE ASSOCIATED WITH C-REACTIVE PROTEIN
LEVELS IN PATIENTS WITH STABLE AND UNSTABLE ANGINA
I. Seljeflot, O. Aase, H.
Eid, T. Lyberg, H. Arnesen, Norway
|
| 17:51 |
THE
CELLULAR IMMUNE RESPONSE TO OXIDISED LDL AGGRAVATES ATHEROSCLEROSIS.
EVIDENCE FROM ADOPTIVE TRANSFER STUDIES IN IMMUNODEFICIENT
MICE
X. Zhou, C. Tenger, A-K.
Robertsson, G.K. Hansson, Sweden
|
| 18:04 |
IMMUNISATION
WITH BACILLUS CALMETTE-GUERIN (BCG) VACCINE ENHANCES AORTIC
ATHEROSCLEROSIS IN CHRONIC LOW LEVEL HYPERCHOLESTEROLAEMIC
RABBITS
W. El-Sankary, M. Tickner, D.J.
Lamb, S. Hourani, L-J. Reynolds,
G.A.A. Ferns, UK
|
| 18:17 |
IMPACT
OF POLYMORPHISMS OF THE IL-6 AND TNF-ALPHA GENES ON CARDIOVASCULAR
RISK MARKERS IN A LARGE POPULATION
A. Jellema, E.J.M. Feskens,
R.P. Mensink, W.H.M. Saris, D. Kromhout, The Netherlands
|
Workshop 22:
VASOACTIVE PEPTIDES AND THEIR RECEPTORS IN ATHEROSCLEROSIS
AND HEART FAILURE |
| Chairpersons: |
M. Huelsmann, Austria
K. Lindstedt, Finland
|
| 17:00 |
BRADYKININ
RECEPTORS IN THE CROSSROADS OF ATHEROSCLEROSIS AND HEART
FAILURE
A. Kuoppala, N. Shiota, J.O. Kokkonen,
I. Liesmaa, K.M. Kostner,
M. Mayranpaa, P.T. Kovanen, K.A. Lindstedt,
Finland, Austria
|
| 17:25 |
EFFECT
OF THE AT1 ANGIOTENSION II RECEPTOR ANTAGONIST IRBESARTAN
ON LESION PROGRESSION AND CHEMOKINE EXPRESSION IN APOE
DEFICIENT MICE
P. Schaeffer, G. Martin,
F. Dol, A-M. Mares, V. Berezowski, B. Staels, D.W. Hum,
J-M. Herbert, France
|
| 17:38 |
ANGIOTENSINOGEN
GENE POLYMORPHISM, PLASMA ANGIOTENSINOGEN, RISK OF HYPERTENSION
AND ISCHEMIC HEART DISEASE: A META-ANALYSIS.
A.A. Sethi, B.G. Nordestgaard, A.
Tybjaerg-Hansen, Denmark
|
| 17:51 |
B-TYPE NATRIURETIC PEPTIDE PREDICTS SUDDEN DEATH IN
PATIENTS WITH CHRONIC HEART FAILURE
R. Berger, M. Huelsman, K.
Strecker, A. Bojic, R. Pacher, B. Stanek, Austria
|
| 18:04 |
INTERLEUKIN
1 RECEPTOR ANTAGONIST GENOTYPE IS ASSOCIATED WITH CORONARY
ATHEROSCLEROSIS IN PATIENTS WITH TYPE 2 DIABETES
R. Marculescu, G. Endler,
M. Schillinger, M. Exner, E. Hayden, K. Huber, O. Wagner,
C. Mannhalter, Austria
|
| 18:17 |
ELEVATED
LEVELS OF SERUM CHEMOKINES JE AND KC IN FEMALE C57BL APOE-/-
VS C3H APOE-/- MICE; POTENTIAL MARKERS OF EARLY ATHEROSCLEROSIS
S.L. Parkin, D.G. Grimsditch,
A. Graham, P.H.E. Groot, K.R. Bruckdorfer, G.M. Benson,
UK
|
| Chairpersons: |
O. Stanger, Austria
W. Herrmann, Germany
|
| 17:00 |
PRINCIPLES
OF HOMOCYSTEINE METABOLISM IN HEALTH AND DISEASE
W. Herrmann, Germany
|
| 17:25 |
CURRENT
PERSPECTIVES IN CLINICAL HOMOCYSTEINE RESEARCH. BACK TO
THE LAB?
O. Stanger, Austria
|
| 17:50 |
EFFECT
OF ISOFLAVONES ON HOMOCYSTEINE AND NITRIC OXIDE DERIVATIVES
IN HYPERCHOLESTEROLEMIC AND HYPERTENSIVE POSTMENOPAUSAL
WOMAN
I.R.O. Pereira, M.C. Bertolami,
A.A. Faludi, J.M. Aldrighi, D.S.P. Abdalla,
Brazil
|
| 18:03 |
HOMOCYSTEINE
AS PREDICTOR OF CLINICAL EVENTS IN PATIENTS WITH PREVIOUS
MYOCARDIAL INFARCTION
I. Seljeflot, M. Hurlen,
B. Christensen, M. Fjeldberg, L.G. Klaboe,
H. Arnesen, Norway
|
| 18:16 |
DISCUSSION |
| | |
